Could a simple supplement tame diabetes and heart risk?

NCT ID NCT07503548

Not yet recruiting Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether tributyrin, a dietary supplement that turns into butyrate in the body, can improve blood sugar control, reduce inflammation, and lower heart disease risk in people with type 2 diabetes. Sixty participants at high risk for heart problems will receive either tributyrin or a placebo alongside their usual diabetes treatment for 12 weeks. The goal is to see if this safe, natural compound can offer extra benefits beyond standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tributyrin (a dietary supplement that turns into butyrate in the body)
What this could lead to: If it works, this could point toward a simple, safe supplement to help manage blood sugar and reduce heart disease risk in people with type 2 diabetes.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The supplement may not show significant benefits over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS

Contacts and locations

Locations

Matareya Teaching Hospital

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.